• LAST PRICE
    0.1709
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.1709
  • Day Range
    ---
  • 52 Week Range
    Low 0.1634
    High 1.0900
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.1635
TimeVolumeNDRA
09:32 ET11810.165
09:42 ET1000.174999
09:55 ET1500.1727
10:06 ET76200.1727
10:13 ET10000.172999
10:15 ET16910.17
10:22 ET4990.1675
10:31 ET4000.1675
11:07 ET22000.1676
11:18 ET1000.171769
12:24 ET62710.1671
12:28 ET1000.167001
12:48 ET229080.1636
01:00 ET67500.1709
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNDRA
ENDRA Life Sciences Inc
10.8M
-0.7x
---
United StatesATHE
Alterity Therapeutics Ltd
16.3M
-1.7x
---
United StatesTOVX
Theriva Biologics Inc
11.1M
-0.5x
---
United StatesCYCC
Cyclacel Pharmaceuticals Inc
10.5M
-0.5x
---
United StatesCING
Cingulate Inc
10.2M
0.0x
---
United StatesQSAM
Qsam Biosciences Inc
10.2M
-0.9x
---
As of 2022-11-28

Company Information

ENDRA Life Sciences Inc. develops technology for increasing the capabilities of clinical diagnostic ultrasound to broaden patient access to the diagnosis and treatment of various medical conditions in circumstances where other diagnostic technologies are unavailable or impractical. The Company has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and stage progression of non-alcoholic fatty liver disease (NAFLD), which untreated, can progress to Non-alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The Company's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.

Contact Information

Headquarters
3600 Green Ct Ste 350ANN ARBOR, MI, United States 48105-2440
Phone
734-335-0468
Fax
302-655-5049

Executives

Chairman of the Board, Chief Executive Officer
Francois Michelon
Chief Technology Officer
Michael Thornton
Senior Director of Finance
Irina Pestrikova
Chief Commercial Officer
Renaud Maloberti
Independent Director
Louis Basenese

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$10.8M
Revenue (TTM)
$0.00
Shares Outstanding
63.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.96
EPS
$-0.25
Book Value
$0.25
P/E Ratio
-0.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.